Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK3 | Q13188 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | PRF1 | P14222 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 5/20 | 0.36 |
| ▸ | HTR7 | P34969 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 3/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972464 | 0.75 | ALDH1A1 (0.33) | HTR1AHTR7KMT2ANMT1BRD4 | |
| SCHEMBL31664536 | 0.70 | KDM4E (0.38) | PRF1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL12670098 | 0.69 | SMO (0.47) | KITKMT2AUSP30BRD4ALDH1A1 | |
| SCHEMBL13200796 | 0.69 | ALDH1A1 (0.69) | KITKMT2AUSP30ALDH1A1SMN1; SMN2 | |
| SCHEMBL5245677 | 0.67 | MCOLN2 (0.61) | HTR1AHTR7USP30SMN1; SMN2 | |
| SCHEMBL29865358 | 0.66 | QDPR (0.34) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14094445 | 0.66 | SMN1; SMN2 (0.56) | HTR1AHTR7KMT2AUSP30ALDH1A1 | |
| SCHEMBL4254479 | 0.65 | MAPK1 (0.67) | HTR1AHTR7KMT2AUSP30ALDH1A1 | |
| SCHEMBL17857839 | 0.65 | HTR2A (0.58) | HTR1AHTR7KMT2ADRD2HTR6 | |
| SCHEMBL21918985 | 0.64 | KDM4E (0.42) | KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | disclosed |
| US-7872139-B2 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | GCK, HK1, HK2 | STK3 536/4885KIT 3435/4885PRF1 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.